We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PAVS:NASDAQParanovus Entertainment Technology Ltd. Analysis

Data as of 2026-06-10 - not real-time

$0.86

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Paranovus Entertainment Technology Ltd. (PAVS) is trading at a deep discount to its book value, with a price‑to‑book ratio of roughly 0.02, indicating severe undervaluation despite a market cap of under $1 M. The technical landscape is bleak: the 14‑day RSI sits near the oversold threshold, the MACD histogram is marginally positive yet the MACD line remains below its signal, and the 30‑day volatility exceeds 90%, all pointing to a fragile price structure. Fundamental metrics reinforce the downside narrative – revenue is modest at $12.4 M, gross and operating margins are negative, EBITDA is a loss of nearly $0.5 M, and both ROE and ROA are firmly in negative territory, while cash flow is negative and the company carries a debt‑to‑equity ratio above 10, underscoring solvency concerns. Liquidity is thin, with daily volume eclipsing the tiny market cap, and the stock has endured a near‑total drawdown of roughly 100%, suggesting extreme downside risk.
The combination of a bearish trend direction, high beta (≈2.0), extreme price volatility, and a sector classification of Consumer Defensive (Packaged Foods) – a space where pricing power is limited – further amplifies the risk profile. Given the lack of any dividend history and a payout ratio of zero, dividend sustainability is non‑existent. In sum, the stock appears dramatically undervalued from a price‑to‑book perspective but is beset by fundamental weakness, acute price volatility, and heightened systematic risk, making it a high‑risk, low‑return proposition at present.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • bearish technical indicators (RSI oversold, MACD bearish)
  • extreme price volatility and near‑total drawdown
  • negative earnings and cash flow

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • price remains deeply discounted to book
  • potential for turnaround if cash burn is curbed
  • still elevated sector and regulatory risk

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • persistent negative margins and ROE/ROA
  • high beta and systematic market exposure
  • lack of dividend or sustainable cash generation

Key Metrics & Analysis

Financial Health

Revenue Growth18033.40%
Profit Margin-54.84%
ROE-21.54%
ROA-3.13%
Debt/Equity10.83
P/B Ratio0.0
Op. Cash Flow$-1862427
Free Cash Flow$2.3M

Technical Analysis

TrendBearish
RSI32.6
Support$0.86
Resistance$26.69
MA 20$1.06
MA 50$1.34
MA 200$320.89
MACDBullish
VolumeIncreasing
Fear & Greed Index83.8

Valuation

Fair Value$81.06
GradeUndervalued
TypeValue

Risk Assessment

Beta1.96
Volatility93.53%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.